Memantine and Catatonic Schizophrenia

Thomas, Christopher R.

doi:10.1176/appi.ajp.162.3.626

Cited by 49 publications

(24 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, studies on the treatment of catatonia suggested that mood stabilizers, particularly carbamazepine, could be an effective medication option for both the acute and maintenance phases of this syndrome [79]. Finally, case-report studies reported the effectiveness of N-methyl-D-aspartate (NMDA) receptor antagonists, specifically amantadine and memantine, for the treatment of catatonia [80,81]. Nevertheless, when considering these other pharmacological options for treatment-resistant catatonia patients, caution is warranted because the literature on these treatments consists only of case reports and retrospective studies (randomized controlled trials are lacking).…”

Section: Treatment Approachesmentioning

confidence: 99%

Catatonia in Patients with Autism: Prevalence and Management

et al. 2014

View full text Add to dashboard Cite

Although recent studies have shown that catatonia can occur in patients with autism spectrum disorders (ASDs), the overlap of the behavioral features between these disorders raises many diagnostic challenges. In fact, in clinical practice it is common to misinterpret catatonic symptoms, including mutism, stereotypic speech, repetitive behaviors, echolalia, posturing, mannerisms, purposeless agitation and rigidity, as features of ASDs. The current medical treatment algorithm for catatonia in ASDs recommends the use of benzodiazepines. Electroconvulsive therapy (ECT) is indicated when patients are unresponsive, or insufficiently responsive, to benzodiazepines. Other pharmacological options are also described for the treatment of catatonic patients resistant to benzodiazepines and ECT, and there is evidence for the effectiveness of a psychological treatment, co-occurring with medical treatments, in order to support the management of these patients. In this article we provide a summary of studies exploring catatonia in ASDs and our clinical experience in the management and treatment of this syndrome through the presentation of three brief case studies. Moreover, we review the mechanisms underlying symptoms of catatonia in ASDs, as well as the diagnostic challenges, providing an outline for the management and treatment of this syndrome in this clinical population.

show abstract

Section: Treatment Approachesmentioning

confidence: 99%

Catatonia in Patients with Autism: Prevalence and Management

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Two recent case reports have found memantine to have a positive and sometimes dramatic response in patients with catatonic schizophrenia (88,89). It is conceptualized that there is a decrease in release of GABA to the supplementary motor areas and therefore less glutamatergic inhibition in catatonia, which would result in a net effect of increased glutamatergic function in the striatum.…”

Section: Treatmentsmentioning

confidence: 99%

Catatonia: A Review

Weder

Muralee

Penland

et al. 2008

Annals of Clinical Psychiatry

View full text Add to dashboard Cite

show abstract

“…Thus, a glutamate antagonist such as memantine may be useful in treating catatonia. Three case reports found memantine 20 mg to be effective in catatonic schizophrenia [54][55][56] .…”

Section: Schizophreniamentioning

confidence: 99%

Memantine: a comprehensive review of safety and efficacy

Kavirajan

2008

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

Background : Memantine is an uncompetitive antagonist of the N -methyl-Daspartate glutamate receptor. It is now approved only for treatment of moderate-to-severe Alzheimer's disease (AD). However, as a growing body of evidence indicates that disturbed glutamate neurotransmission may be central to the pathophysiology of such conditions as obesity, schizophrenia, depression, substance abuse, pain disorders and glaucoma, clinical trials have explored the role of memantine in these and other disorders. Objective : To provide a comprehensive review of the safety and efficacy of memantine across the range of clinical applications in which it has been studied. Methods : A search was done on Pubmed using keyword 'memantine' to identify clinical trials of memantine. Results/conclusion : At present, clinical trial evidence supports the use of memantine in only moderate-to-severe AD. Preliminary studies suggest benefit in frontotemporal dementia, alcohol dependence, post-traumatic stress disorder, headache and obesity, but rigorous clinical trials are needed to confirm these results. Available data indicate that across a range of clinical applications, memantine is a safe and well-tolerated drug.

show abstract

Memantine and Catatonic Schizophrenia

Cited by 49 publications

References 5 publications

Catatonia in Patients with Autism: Prevalence and Management

Catatonia in Patients with Autism: Prevalence and Management

Catatonia: A Review

Memantine: a comprehensive review of safety and efficacy

Contact Info

Product

Resources

About